Literature DB >> 24753158

Saturated free fatty acids induce cholangiocyte lipoapoptosis.

Sathish Kumar Natarajan1, Sally A Ingham, Ashley M Mohr, Cody J Wehrkamp, Anuttoma Ray, Sohini Roy, Sophie C Cazanave, Mary Anne Phillippi, Justin L Mott.   

Abstract

UNLABELLED: Recent studies have identified a cholestatic variant of nonalcoholic fatty liver disease (NAFLD) with portal inflammation and ductular reaction. Based on reports of biliary damage, as well as increased circulating free fatty acids (FFAs) in NAFLD, we hypothesized the involvement of cholangiocyte lipoapoptosis as a mechanism of cellular injury. Here, we demonstrate that the saturated FFAs palmitate and stearate induced robust and rapid cell death in cholangiocytes. Palmitate and stearate induced cholangiocyte lipoapoptosis in a concentration-dependent manner in multiple cholangiocyte-derived cell lines. The mechanism of lipoapoptosis relied on the activation of caspase 3/7 activity. There was also a significant up-regulation of the proapoptotic BH3-containing protein, PUMA. In addition, palmitate-induced cholangiocyte lipoapoptosis involved a time-dependent increase in the nuclear localization of forkhead family of transcription factor 3 (FoxO3). We show evidence for posttranslational modification of FoxO3, including early (6 hours) deacetylation and dephosphorylation that coincide with localization of FoxO3 in the nuclear compartment. By 16 hours, nuclear FoxO3 is both phosphorylated and acetylated. Knockdown studies confirmed that FoxO3 and its downstream target, PUMA, were critical for palmitate- and stearate-induced cholangiocyte lipoapoptosis. Interestingly, cultured cholangiocyte-derived cells did not accumulate appreciable amounts of neutral lipid upon FFA treatment.
CONCLUSION: Our data show that the saturated FFAs palmitate and stearate induced cholangiocyte lipoapoptosis by way of caspase activation, nuclear translocation of FoxO3, and increased proapoptotic PUMA expression. These results suggest that cholangiocyte injury may occur through lipoapoptosis in NAFLD and nonalcoholic steatohepatitis patients.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24753158      PMCID: PMC4553418          DOI: 10.1002/hep.27175

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  40 in total

1.  Cell-free activation of a DNA-binding protein by epidermal growth factor.

Authors:  H B Sadowski; M Z Gilman
Journal:  Nature       Date:  1993-03-04       Impact factor: 49.962

2.  Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling.

Authors:  Anatoliy I Masyuk; Bing Q Huang; Brynn N Radtke; Gabriella B Gajdos; Patrick L Splinter; Tatyana V Masyuk; Sergio A Gradilone; Nicholas F LaRusso
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-04-11       Impact factor: 4.052

3.  Triglyceride accumulation protects against fatty acid-induced lipotoxicity.

Authors:  Laura L Listenberger; Xianlin Han; Sarah E Lewis; Sylvaine Cases; Robert V Farese; Daniel S Ory; Jean E Schaffer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

4.  Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis.

Authors:  Jiang Wei Wu; Shu Pei Wang; Fernando Alvarez; Stéphanie Casavant; Nicolas Gauthier; Lynda Abed; Krishnakant G Soni; Gongshe Yang; Grant A Mitchell
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

5.  A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease.

Authors:  P Sorrentino; G Tarantino; A Perrella; P Micheli; O Perrella; P Conca
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

6.  Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

Authors:  Kanji Yamaguchi; Liu Yang; Shannon McCall; Jiawen Huang; Xing Xian Yu; Sanjay K Pandey; Sanjay Bhanot; Brett P Monia; Yin-Xiong Li; Anna Mae Diehl
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

7.  Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase.

Authors:  Anne Brunet; Lora B Sweeney; J Fitzhugh Sturgill; Katrin F Chua; Paul L Greer; Yingxi Lin; Hien Tran; Sarah E Ross; Raul Mostoslavsky; Haim Y Cohen; Linda S Hu; Hwei-Ling Cheng; Mark P Jedrychowski; Steven P Gygi; David A Sinclair; Frederick W Alt; Michael E Greenberg
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

8.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.

Authors:  Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

9.  Compensatory role of inducible annexin A2 for impaired biliary epithelial anion-exchange activity of inflammatory cholangiopathy.

Authors:  Osamu Kido; Koji Fukushima; Yoshiyuki Ueno; Jun Inoue; Douglas M Jefferson; Tooru Shimosegawa
Journal:  Lab Invest       Date:  2009-10-12       Impact factor: 5.662

10.  Ginsenoside Rg3 Suppresses Palmitate-Induced Apoptosis in MIN6N8 Pancreatic beta-Cells.

Authors:  Kyong Kim; Min Park; Hye Young Kim
Journal:  J Clin Biochem Nutr       Date:  2009-12-29       Impact factor: 3.114

View more
  21 in total

1.  High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis.

Authors:  Fatjon Leti; Ivana Malenica; Meera Doshi; Amanda Courtright; Kendall Van Keuren-Jensen; Christophe Legendre; Christopher D Still; Glenn S Gerhard; Johanna K DiStefano
Journal:  Transl Res       Date:  2015-05-04       Impact factor: 7.012

2.  Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH).

Authors:  Z Wang; Z Zhao; Y Xia; Z Cai; C Wang; Y Shen; R Liu; H Qin; J Jia; G Yuan
Journal:  J Endocrinol Invest       Date:  2022-02-28       Impact factor: 4.256

Review 3.  The hedgehog pathway in nonalcoholic fatty liver disease.

Authors:  Mariana Verdelho Machado; Anna Mae Diehl
Journal:  Crit Rev Biochem Mol Biol       Date:  2018-03-20       Impact factor: 8.250

4.  Downregulation of p16 Decreases Biliary Damage and Liver Fibrosis in the Mdr2/ Mouse Model of Primary Sclerosing Cholangitis.

Authors:  Konstantina Kyritsi; Heather Francis; Tianhao Zhou; Ludovica Ceci; Nan Wu; Zhihong Yang; Fanyin Meng; Lixian Chen; Leonardo Baiocchi; Debjyoti Kundu; Lindsey Kennedy; Suthat Liangpunsakul; Chaodong Wu; Shannon Glaser; Gianfranco Alpini
Journal:  Gene Expr       Date:  2020-05-11

5.  Acetylcholine reduces palmitate-induced cardiomyocyte apoptosis by promoting lipid droplet lipolysis and perilipin 5-mediated lipid droplet-mitochondria interaction.

Authors:  Qing Wu; Ming Zhao; Xi He; Runqing Xue; Dongling Li; Xiaojiang Yu; Shengpeng Wang; Weijin Zang
Journal:  Cell Cycle       Date:  2021-08-23       Impact factor: 5.173

6.  Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.

Authors:  Lixian Chen; Nan Wu; Shannon Glaser; Gianfranco Alpini; Lindsey Kennedy; Heather Francis; Ludovica Ceci; Tianhao Zhou; Niharika Samala; Konstantina Kyritsi; Chaodong Wu; Amelia Sybenga; Burcin Ekser; Wasim Dar; Constance Atkins; Vik Meadows
Journal:  Hepatology       Date:  2021-07-29       Impact factor: 17.298

Review 7.  Role of 3-Hydroxy Fatty Acid-Induced Hepatic Lipotoxicity in Acute Fatty Liver of Pregnancy.

Authors:  Sathish Kumar Natarajan; Jamal A Ibdah
Journal:  Int J Mol Sci       Date:  2018-01-22       Impact factor: 5.923

8.  FoxO3 increases miR-34a to cause palmitate-induced cholangiocyte lipoapoptosis.

Authors:  Sathish Kumar Natarajan; Bailey A Stringham; Ashley M Mohr; Cody J Wehrkamp; Sizhao Lu; Mary Anne Phillippi; Dee Harrison-Findik; Justin L Mott
Journal:  J Lipid Res       Date:  2017-03-01       Impact factor: 5.922

Review 9.  Autophagy: a new target for nonalcoholic fatty liver disease therapy.

Authors:  Yuqing Mao; Fujun Yu; Jianbo Wang; Chuanyong Guo; Xiaoming Fan
Journal:  Hepat Med       Date:  2016-03-24

10.  Inhibition of insulin-like growth factor II (IGF-II)-dependent cell growth by multidentate pentamannosyl 6-phosphate-based ligands targeting the mannose 6-phosphate/IGF-II receptor.

Authors:  Megan E Zavorka; Christopher M Connelly; Rosslyn Grosely; Richard G MacDonald
Journal:  Oncotarget       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.